- Home
- CGEN vs BTMD Comparison
CGEN vs BTMD Comparison
Compare CGEN & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- BTMD
- Stock Information
- Founded
- CGEN 1993
- BTMD 2012
- Country
- CGEN Israel
- BTMD United States
- Employees
- CGEN N/A
- BTMD N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- CGEN Health Care
- BTMD Health Care
- Exchange
- CGEN Nasdaq
- BTMD Nasdaq
- Market Cap
- CGEN 149.6M
- BTMD 136.0M
- IPO Year
- CGEN 2000
- BTMD N/A
- Fundamental
- Price
- CGEN $1.56
- BTMD $3.93
- Analyst Decision
- CGEN Strong Buy
- BTMD Strong Buy
- Analyst Count
- CGEN 1
- BTMD 1
- Target Price
- CGEN $4.00
- BTMD $8.00
- AVG Volume (30 Days)
- CGEN 299.7K
- BTMD 307.7K
- Earning Date
- CGEN 03-04-2025
- BTMD 03-12-2025
- Dividend Yield
- CGEN N/A
- BTMD N/A
- EPS Growth
- CGEN N/A
- BTMD N/A
- EPS
- CGEN N/A
- BTMD 0.09
- Revenue
- CGEN $27,864,000.00
- BTMD $197,191,000.00
- Revenue This Year
- CGEN $22.94
- BTMD $17.51
- Revenue Next Year
- CGEN $15.88
- BTMD $15.84
- P/E Ratio
- CGEN N/A
- BTMD $42.44
- Revenue Growth
- CGEN N/A
- BTMD 6.38
- 52 Week Low
- CGEN $1.35
- BTMD $3.04
- 52 Week High
- CGEN $2.66
- BTMD $8.44
- Technical
- Relative Strength Index (RSI)
- CGEN 38.91
- BTMD 43.14
- Support Level
- CGEN $1.54
- BTMD $3.80
- Resistance Level
- CGEN $1.64
- BTMD $4.47
- Average True Range (ATR)
- CGEN 0.08
- BTMD 0.30
- MACD
- CGEN 0.01
- BTMD 0.04
- Stochastic Oscillator
- CGEN 26.92
- BTMD 61.64
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.